S-1 Impact 6/10 Ipo / Direct Listing

BirchBioMed Inc.

November 19, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

BirchBioMed Inc. filed Amendment No. 2 to its S-1 to register resale of up to 30,882,423 common shares (29,925,851 outstanding shares plus 17,605 shares and 938,967 warrant shares to Streeterville Capital) in connection with a direct listing on Nasdaq under symbol BRBM. The offering is not underwritten on a firm-commitment basis; the company receives no proceeds from shareholder resales. The company is an emerging growth company and smaller reporting company, and will remain a controlled company with Mark Miller and Susan Elliott holding over 50% voting power.

  • Registers resale of up to 30,882,423 common shares for Nasdaq direct listing under symbol BRBM.
  • No firm-commitment underwriter; company receives no proceeds from Registered Shareholder sales.
  • Streeterville purchase agreement allows future share issuance at initial $8.52 per share, subject to adjustments.
  • Converted $9.08M face value of convertible notes into 3,308,737 shares on February 15, 2026; no notes outstanding.
  • Controlled company: Miller and Elliott hold over 50% voting power post-offering.

Price data unavailable.

A pre-revenue biotech pursuing a novel Nasdaq direct listing with no underwriter, exposing investors to unusual price-discovery and volatility risk.

Direct listing without a firm-commitment underwriter is a novel, higher-volatility path to public trading versus a traditional IPO.

No public market exists; direct listing price discovery may be volatile. Nasdaq approval is a condition and not assured; failure terminates the listing.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →